UK markets closed
  • NIKKEI 225

    27,819.33
    -180.63 (-0.65%)
     
  • HANG SENG

    20,082.43
    +471.59 (+2.40%)
     
  • CRUDE OIL

    94.22
    +2.29 (+2.49%)
     
  • GOLD FUTURES

    1,803.80
    -9.90 (-0.55%)
     
  • DOW

    33,336.65
    +27.14 (+0.08%)
     
  • BTC-GBP

    19,803.37
    +367.40 (+1.89%)
     
  • CMC Crypto 200

    571.80
    -2.94 (-0.51%)
     
  • ^IXIC

    12,779.13
    -75.68 (-0.59%)
     
  • ^FTAS

    4,131.26
    -19.42 (-0.47%)
     

Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance

  • Oops!
    Something went wrong.
    Please try again later.
·9-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Cosmo Pharmaceuticals N.V. / Key word(s): Half Year Results

28-Jul-2022 / 06:06 GMT/BST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Ad hoc announcement pursuant to Art. 53 LR

Dublin, Ireland – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced strong financial half-year 2022 results, with record revenue of €41.5 million up 46.1% (H1 2021: €28.4 million), EBITDA of €14.9 million up 338.2% (H1 2021: €3.4 million), operating profit of €8.1 million (H1 2021: €0.008 million), profit before tax €9.0 million (H1 2021: loss before tax €4.7 million) and reaffirms 2022 full-year guidance.

Product and Business Highlights:

  • Medtronic is placing GI Genius™ devices in hospitals worldwide with over 850 devices to date contracted by Medtronic with clients both in U.S. and EU. Commercial negotiations are ongoing in the U.S. between Medtronic and potential clients representing over 6,000 endoscopic towers (estimated 20% of the U.S. market).

  • The first U.S. trial using GI Genius™, published in March in Gastroenterology, the official medical journal of the American Gastroenterological Association, showed that the use of GI Genius™ significantly decreases the miss rate (2x) of colorectal polyps and adenomas compared to standard colonoscopy.

  • Additional features and applications are under development to broaden the scope of GI Genius™. A landmark paper was published in Nature Digital Medicine. (the paper on the new GI Genius CADx).

  • Winlevi® is one of the most successful launches in the U.S. topical acne market over the last 15 years with over 10,000 dermatologists prescribing over 258,000 TRx’s to date. 

  • Cortiment® achieved a major commercial milestone with cumulative net sales by our partner Ferring reaching €100 million, triggering an €8 million milestone payment to Cosmo.  

  • Cortiment® NDA for Japan accepted by Japan’s Pharmaceuticals and Medical Devices Agency following submission by our partner, Ferring, the review is expected to last approximately one year.

  • Eleview® agreement with Medtronic was expanded to all countries except Canada where it is already licenced to Pharmascience.

  • Preparations for Breezula® phase 3 trial in males are underway with trial expected to begin in the 2nd half of this year.

  • CB-03-10 (cortexolone 17 α-valerate-21-propionate) phase I study in patients with advanced refractory solid tumors has begun, clinical sites in the U.S. have been activated and screening of patients has commenced.

  • CB-01-33 (colesevelam) formulation and IP protection under completion.

  • After the close of H1, the Winlevi® agreement with Sun was expanded to include Japan, Australia, New Zealand, Brazil, Mexico and Russia. Cosmo will receive an upfront payment of US$ 7 million, potential regulatory and sales milestones and customary double-digit royalties on net sales and will be the exclusive supplier of the product. 

  • In addition, another important agreement was signed after the close of H1. Winlevi® has been licensed to 3SBio for Greater China. Cosmo will receive an upfront payment of US$ 6.5 million, potential regulatory and sales milestones and customary ascending high single digit or double-digit royalties on net sales.

Revenue Performance   
Total revenues were €41.5 million for the first half of 2022, as compared to €28.4 million in the first half of 2021, an increase of €13.1 million, or 46.1%.

EBITDA
EBITDA was €14.9 million for the first half of 2022, as compared to €3.4 million in the first half of 2021, an increase of €11.5 million, or 338.2% reflecting the increase in revenue and tight control over operating expenses. 

Operating Profit
Net operating expenses were €33.4 million for the first half of 2022, as compared to €28.4 million in the first half of 2021, an increase of €5.0 million, or 17.6%. The increase is mainly due to the non-cash amortization of intangible asset, Winlevi®, of €3.4 million and an increase in raw materials and consumables associated with an increase in product sales. Operating profit was €8.1 million for the first half 2022, as compared to €0.008 million in the first half of 2021.  

Profit Before Tax
Financial income/expenses were €1.0 million in the first half of 2022 compared to net financial expenses of €1.9 million in the first half of 2021, the movement versus the prior year is mainly attributable to a net foreign exchange gain of €3.4 million. The prior year included a share in the results of associate loss of €2.8 million. Profit before tax was €9.0 million compared to a loss before tax of €4.7 million in the first half of 2021.  

Net Cashflow From Operating Activities 
Net cash generated from operating activities was €12.6 million in the first half of 2022 compared to net cash generated from operating activities of €9.7 million in the first half of 2021.   

Statement of Financial Position Highlights
Cash and fund investments were €219.0 million as at 30 June 2022 compared to €222.2 million at 31 December 2021. Equity attributable to owners of the Company was €462.5 million as at 30 June 2022 vs. €505.3 million at 31 December 2021.

Key figures:

EUR /000

H1 2022

H1 2021

Income statement

 

 

Revenues

41,511

28,420

Net operating expenses

(33,403)

(28,412)

Operating profit

8,108

8

Net financial expense

981

(1,916)

Share of result of associates

-

(2,759)

Profit / (Loss) before taxes

9,089

(4,667)

Profit / (Loss) after taxes for the period

7,896

(5,741)

 

 

 

EUR /000

H1 2022

FY 2021

Statement of financial position

 

 

Non-current assets

492,814

529,713

Cash and cash equivalents

218,027

198,560

Other current assets

54,411

77,289

Liabilities

296,032

292,884

Equity attributable to owners of the Company

462,535

505,276

Non-controlling interests

6,685

7,402

Equity ratio (%)

60.4%

62.7%

 

 

 

Shares

 

 

Weighted average number of shares

16,531,105

14,392,984

Earnings/(loss) per share (in EUR)

0.476

(0.399)


Mauro Ajani, Chairman of Cosmo, said: “I am happy to see that our investments to move towards large markets over the past years are beginning to pay off”. 

Alessandro Della Chà, Chief Executive Officer, said: “I am proud to see Cosmo closing its best half-year in terms of revenues. Cosmo is at the forefront of substantial innovations that are starting to have a positive impact on our financial performance. We have exciting products in large markets, a full franchise in Artificial Intelligence which is just beginning to gain traction, a great pipeline and a solid balance sheet. Our objective is now to deliver according to guidance, and I am confident we will do so”.

2022 Financial Outlook
Cosmo confirmed its guidance for the full year 2022 of:

  • Total revenues in the range of €90m - €100m vs €65.1m in 2021.

  • Operating profit in the range of €20m - €25m vs €11.1m in 2021.

The Half-year Report 2022 with further information was published today, 28 July 2022 at 07:00 am CEST and is available for download at: 

http://www.cosmopharmaceuticals.com/investor-relations/financial-reports 

Live conference call and video webcast presentation:

Date:

Thursday, 28 July 2022

Time:

2:00 pm CEST

Participant webcast link: Chrome (recommended) or Firefox 
https://event.choruscall.com/mediaframe/webcast.html?webcastid=08a78URt
Please note that there is a function to type in your questions via webcast. 

Via phone
Participants wishing to ask verbal questions via phone, may call the following numbers below. To ensure prompt access, please call approximately ten minutes prior to the scheduled start of the call.

Switzerland / Europe

+41 (0) 58 310 50 00

United Kingdom

+44 (0) 207 107 06 13

United States

+1 (1) 631 570 56 13

The presentation and press release as well as the Half-Year Report 2022 will be available for download as of 07:00 am CEST on 28 July 2022 at www.cosmopharma.com.

Replay
The webcast, along with the presentation will be available online shortly after the event and accessible for three months.

Upcoming Calendar of Events

 

Commerzbank and ODDO BHF Conference

September 6-8, 2022

Investora Conference, Zurich

September 21, 2022

Credit Suisse Equity Forum Switzerland

November 15-17, 2022

Jefferies 2022 London Healthcare Conference

November 15-17, 2022

Deutsches Eigenkapitalforum, Frankfurt

November 28-30, 2022

About Cosmo
Cosmo is a pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders, to improve endoscopy quality measures through aiding the detection of colonic lesions and to treat selected dermatological conditions. Cosmo develops and manufactures products which are distributed globally by selected partners including Lialda®, Uceris®/Cortiment® and Winlevi®. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius™ which uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo® to Red Hill Biopharma Ltd. for the US and has licensed Relafalk® to Dr. Falk Gmbh for the EU and other countries. The company also has a rich development pipeline. For additional information on Cosmo and its products please visit the Company’s website: www.cosmopharma.com

Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.

Contact
Hazel Winchester, 
Head of Investor Relations
Cosmo Pharmaceuticals N.V. 
Tel: +353 1 817 03 70
hwinchester@cosmopharma.com


End of ad hoc announcement

Language:

English

Company:

Cosmo Pharmaceuticals N.V.

Riverside 2, Sir John Rogerson’s

Dublin 2 Dublin

Ireland

Phone:

+ 353 1 817 0370

E-mail:

info@cosmopharma.com

Internet:

https://www.cosmopharma.com/

ISIN:

NL0011832936

Listed:

SIX Swiss Exchange

EQS News ID:

1407623


 

End of Announcement

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting